Achieve Life Sciences (NASDAQ: ACHV) reported Q3 EPS of ($0.45), $0.15 worse than the analyst estimate of ($0.30).

"It has been a busy and eventful quarter with progressive data analysis further reinforcing the strength of the ORCA-1 Phase 2b trial and the potential for cytisinicline as a new treatment for the millions of people who are battling nicotine addiction," commented Rick Stewart, Chairman and Chief Executive Officer of Achieve. "Our key priority in the fourth quarter is to advance the ongoing, extensive preparations for the Phase 3 clinical trials, including our upcoming meeting with the FDA to finalize the cytisinicline Phase 3 protocols."

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.